There have been several
noteworthy developments in the
drug space recently, which will likely have a material impact on the companies in this sector and the markets they serve. Companies mentioned in this review include
Pfizer Inc. (PFE),
Merck & Co. (MRK),
Johnson & Johnson (JNJ), and Actavis (ACT).
Read more
Modern vending machines can offer investors much more than just soda and snacks. As more companies
incorporate this
automated retail technology into their overall businesses, new avenues of
growth will undoubtedly begin to materialize.
Read more
There have been several noteworthy developments in the
drug space recently, which will likely have a material impact on the companies in this sector and the markets they serve. Companies mentioned in this review include
Pfizer Inc. (PFE),
Merck & Co. (MRK), and
GlaxoSmithKline (GSK).
Read more
Equities remained on a solid uptrend in the first quarter of 2013, with several of the broader indices carving out new all-time highs. Meanwhile, the
Dogs of the Dow continued to impress, outperforming the 30 industrials for a third consecutive month.
Read more
The weak
March government nonfarm payroll report almost certainly means the Federal Reserve will continue its monthly strategy of buying billions of dollars worth of United States Treasuries and mortgage-backed securities in the near future. That strategy promises to expand the
Fed’s balance sheet even more than it has in recent years. But the central bank knows there are limits to what its policies can do.
Read more
During the most recent economic downturn, many
biotech, medical, and pharmaceutical companies turned to outsourcing as a way to boost bottom-line performance. In times of economic weakness, some companies will instinctively react by implementing cost-reduction strategies.
Read more
The
Federal Reserve Board recently finished testing 18 large banks and financial services companies to determine how they might hold up in an extremely stressful environment. The results of the exercise were mixed, and some think the tests aren’t useful, but we think they are here to stay.
Read more
One useful investment tool the
Value Line Investment Survey offers is a list of stocks with the highest
3- to 5-year capital appreciation potential. In this article, we take a glimpse at the stories behind five of these stocks.
Read more
